AURAAura Biosciences, Inc.
Aura Biosciences, Inc. (AURA) develops precision therapies for solid tumors, with a focus on preserving organ function. The next catalyst is Oct 20, 2026 — Phase 1b/2 NMIBC Data Readout, which will test the company’s ability to deliver early-stage clinical results in non-muscle-invasive bladder cancer. The data will provide critical insight into the safety and efficacy of its lead candidate, setting the stage for future trials and investor sentiment.
- Revenue model: Aura generates revenue through upfront payments, milestone-based payments, and royalties from partnerships, with a heavy reliance on clinical trial progress and regulatory approvals.
- Cash flow: Free cash flow has been negative for multiple quarters, reflecting the high capital intensity of clinical development.
- Leverage: The company has a net loss of $139.14M and a diluted EPS of -0.48 as of Q2 2026, with shareholders’ equity at $136.91M.
The Read
Aura Biosciences' stock rallied over 17% on accelerated Phase 3 enrollment and positive formulation data in early 2026 but dropped over 30% after a dilutive $299M equity raise and CEO change overshadowed EPS in Q2.
The schedule
- Tue20Oct
The data readout tests the strength of the Phase 1b/2 NMIBC results, which could influence investor sentiment and valuation. This differs from the last print where the focus was on guidance and cash runway, not trial outcomes.
- Thu12Nov
The earnings release will test the market's reaction to updated guidance, revenue, and cash flow expectations. This is a critical event for assessing the company's financial health and future direction.
- Tue12Jan
The completion of Phase 3 trial enrollment will test the market's confidence in the trial's feasibility and the company's ability to meet enrollment targets. This is a key milestone for regulatory approval and investor sentiment.
- Wed20Jan
This event tests the market's anticipation of the CoMpass trial top-line results. Institutional positioning can signal confidence or uncertainty about the trial's potential outcome.
- Sun14Feb
The earnings release will test the market's reaction to updated guidance, revenue, and cash flow expectations. This is a critical event for assessing the company's financial health and future direction.
- Mon10May
The earnings release will test the market's reaction to updated guidance, revenue, and cash flow expectations. This is a critical event for assessing the company's financial health and future direction.
- Wed11Aug
The earnings release will test the market's reaction to updated guidance, revenue, and cash flow expectations. This is a critical event for assessing the company's financial health and future direction.
Past
- Wed12Aug
Actual outcome: Bull · $7.69 at outcome
Aura Biosciences reported in-line Q2 earnings with an EPS of -$0.50, meeting estimates exactly. The stock pushed past the bull target as investors reacted positively to the company's stabilized financial position following a recent $299M capital raise and C-suite overhaul. Confidence was further bolstered by the fully enrolled Phase 3 CoMpass trial for Bel-sar and strong Phase 2 data showing 80% tumor control, reassuring the market of AURA's long-term clinical prospects.
First quarterly earnings report following the major $299M equity financing and unexpected CEO transition.
- Mon11May
Actual outcome: Bear · $7.98 at outcome
Aura Biosciences reported Q1 2026 EPS of -$0.40, exactly meeting analyst estimates, and highlighted a strengthened balance sheet following a recent $299 million equity financing that extended its cash runway into the second half of 2028. Despite positive updates regarding the Phase 3 CoMpass trial advancing toward enrollment completion and the appointment of a new CEO, the stock saw a muted reaction, falling slightly by 2.6% as the market had already digested the major capital raise and leadership transition announced earlier in the month.
Aura reports Q1 earnings, with intense scrutiny on its remaining liquidity profile and the pacing of its Phase 3 CoMpass trial in early-stage choroidal melanoma.
- Mon30Mar
Actual outcome: Bull · $6.20 at outcome
Aura Biosciences met EPS estimates and provided significant positive updates, including the accelerated enrollment of its Phase 3 CoMpass trial and the successful stability testing of a new formulation for non-ocular solid tumors. While the stock saw a minor initial dip, the confirmation of mid-2026 clinical milestones and a 22% reduction in short interest drove a sustained rally that pushed the price well beyond the bull target by the run date.
Management update on cash position and runway through 2026.